BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dessources K, Miller KM, Kertowidjojo E, Da Cruz Paula A, Zou Y, Selenica P, da Silva EM, Benayed R, Ashley CW, Abu-Rustum NR, Dogan S, Soslow RA, Hensley ML, Weigelt B, Chiang S. ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. Mod Pathol 2022;35:972-8. [PMID: 34961764 DOI: 10.1038/s41379-021-01003-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Dermawan JK, Dashti N, Chiang S, Turashvili G, Dickson BC, Ellenson LH, Kirchner M, Stenzinger A, Mechtersheimer G, Agaimy A, Antonescu CR. Expanding the molecular spectrum of gene fusions in endometrial stromal sarcoma: Novel subunits of the chromatin remodeling complexes PRC2 and NuA4/TIP60 as alternative fusion partners. Genes Chromosomes Cancer 2023;62:152-60. [PMID: 36445224 DOI: 10.1002/gcc.23109] [Reference Citation Analysis]
2 Yang P, Lu J, Zhang P, Zhang S. Comprehensive Analysis of Prognosis and Immune Landscapes Based on Lipid-Metabolism- and Ferroptosis-Associated Signature in Uterine Corpus Endometrial Carcinoma. Diagnostics (Basel) 2023;13. [PMID: 36900015 DOI: 10.3390/diagnostics13050870] [Reference Citation Analysis]
3 Hu X, Zhao S, Cai Y, Swain SS, Yao L, Liu W, Yan T, Herrera-calderon O. Network Pharmacology-Integrated Molecular Docking Reveals the Expected Anticancer Mechanism of Picrorhizae Rhizoma Extract. BioMed Research International 2022;2022:1-16. [DOI: 10.1155/2022/3268773] [Reference Citation Analysis]
4 Yamaguchi K. Personalized Treatment in Uterine Sarcoma. Personalization in Gynecologic Oncology 2022. [DOI: 10.1007/978-981-19-4711-7_4] [Reference Citation Analysis]